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Primary human osteoblasts and osteoclasts incubated in a rotating coculture system
without any scaffolding material, form bone-like tissue that may be used to evaluate
effects of various compounds on mechanical strength. Circulating adiponectin has
been found to be negatively associated with BMD and strength and was therefore
assessed in this system. Osteospheres of human osteoblasts and osteoclasts were
generated with and without adiponectin. The osteospheres were scanned using
micro-computed tomography, the mechanical properties were tested by flat punch
compression using nanoindentation equipment, and the cellular morphology characterized by microscopy. The association between autologously produced adiponectin
and biomechanical properties was further evaluated by quantitation of adiponectin
levels using quantitative polymerase chain reaction (qPCR) and immunoassays, and
identification of stiffness by bending test of rat femurs. The molecular mechanisms
were examined in vitro using human bone cells. Mechanical testing revealed that
adiponectin induced a more compliant osteosphere compared with control. The
osteospheres had a round, lobulated appearance with morphologically different areas;
inner regions containing few cells embedded in a bone-like material surrounded by an
external area with a higher cell quantity. The expression of adiponectin was found to
correlate positively to ultimate bending moment and ultimate energy absorption and
deflection, on the other hand, it correlated negatively to bending stiffness, indicating
autocrine and/or paracrine effects of adiponectin in bone. Adiponectin enhanced
proliferation and expression of collagen, leptin, and tumor necrosis factor-alpha in
osteoblasts and stimulated proliferation, but not the functional activity of osteoclasts.
Our results indicate that both administration of adiponectin during osteosphere production and in situ elevated levels of adiponectin in rat femurs, reduced stiffness of
the bone tissues. An increase in undifferentiated cells and extracellular matrix proteins,
such as collagen, may explain the reduced bone stiffness seen in the osteospheres
treated with adiponectin.
Keywords: adiponectin, bone stiffness, bone remodeling, osteospheres, three-dimensional culturing system
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INTRODUCTION

Adiponectin may act via its receptors, adiponectin receptor 1 and adiponectin receptor 2, that have been found to be
expressed in osteoblasts (30) and osteoclasts (31). However,
studies have demonstrated that adiponectin can affect osteoblasts through both direct and indirect mechanisms inclu
ding; favoring of osteogenesis in mesenchymal progenitor cells
(32, 33), stimulation of osteoblast proliferation and differentiation (34–37), and decrease in the sympathetic tone in osteoblasts via neurons of the locus coeruleus resulting in increased
bone mass (28, 33). The globular domain of adiponectin shows
structural similarity to tumor necrosis factor-α (TNF-α), recep
tor activator of nuclear factor κB ligand (RANKL), and osteoprotegerin (OPG), which all are involved in the regulation of
osteoclastogenesis (38). The described effects of adiponectin
on osteoclastogenesis are multiple and deviating. Most studies
report suppressive (33, 36, 39–41), while others enhancing effects
(42, 43) of adiponectin on osteoclast differentiation. Based on
the previous observations our hypothesis was that osteospheres
produced in a rotational coculture in vitro could be used as a
model system to study changes in bone mechanical properties.
Since circulating adiponectin levels are found to be negatively
associated with fracture risk, we wanted to investigate both
the effects of adiponectin administration in vitro, and changes
in the level of autologously produced adiponectin in vivo, on
the biomechanical properties of bone. Moreover, we aimed to
identify the molecular mechanisms of adiponectin on single
cell cultures of human osteoblasts and osteoclasts.

Cultivation of cells has traditionally been a cost-effective way
to evaluate the results of a treatment without having to involve
animals in larger and more expensive studies. Recently, there has
been increasing evidence that three-dimensional (3D) culturing
systems provide more accurate information than two-dimensional
(2D) systems because of the more relevant architectural microenvironment that improves cell–cell interaction and cell-extracellular
matrix (ECM) interaction (1–3). In bone, osteoblasts, osteocytes,
and osteoclasts are the main cell types involved in building,
maintenance and repair of bone, cooperating in a complex manner. During remodeling of bone, cells are situated in discrete
anatomical multicellular units called the Basic Multicellular Unit
(BMU), and 3D culturing systems have been created to mimic
the BMU environment (4–9). Different scaffolding materials
(natural and/or synthetic) have been used in the production and
investigation of bone in vitro (4, 6, 10, 11). Recently, a model
of bone formation has been presented, where two calcium
phosphate scaffolds were used as anchors and cells grown on a
fibrin gel cast in between (12). However, the presence of scaffolds
makes it challenging to investigate the effect of a substance on
the mechanical properties of the artificial bone cell constructs.
Primary human osteoblast and osteoclast precursor cells can
be mixed in a rotating cell culture system (RCCS) to generate
3D mineralized tissue constructs called osteospheres, where the
cells form their own ECM components (9). In these osteospheres,
osteoblasts and osteoclasts surround a porous mineralized matrix
containing embedded osteocytes (9). These bone-like tissues
may be used to test the effect of different substances on bone
mechanical properties. Adiponectin has been shown to influence
the metabolism and mechanical properties of bone (13–15) and
was therefore investigated in this study.
Adiponectin was identified in 1995 by several research groups
(16–19). It occurs in different forms in plasma including a
globular domain and full-length adiponectin that may aggregate
into oligomer forms including a trimer, a hexamer, and heavier,
multimer forms. The functions of adiponectin vary dependent on
the target organ and its isoforms (20).
The main physiological role of adiponectin is considered
to be related to metabolic regulation and energy homeostasis
(20, 21). Adiponectin levels are abundant in circulation relative
to other hormones, and although it is produced by adipose tissue, plasma concentrations of adiponectin has been negatively
associated with increasing obesity (22) and type 2 diabetes
(23, 24). Furthermore, serum adiponectin has been shown to be
a predictor of fractures in type 2 diabetic patients (25).
An inverse correlation between circulating adiponectin levels
and different bone parameters, including BMD (14, 15), axial stiffness and maximal load (26), has been reported in various patient
groups in humans. However, the effects of adiponectin on bone
in animal studies are inconclusive (13). Shinoda et al. reported
no particular changes in the bone phenotype of adiponectinknockout (APN-KO) mice (27), while Kajimura et al. observed
stiffer bones in the same type of animals (APN-KO) (28).
To further complicate the matter, exercise has been found to
increase both adiponectin levels and bone mass in rats (29).
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MATERIALS AND METHODS
Preparation of Osteospheres From
Primary Human Osteoblasts and
Osteoclasts

Commercially available primary human osteoblasts (NHO)
(Cambrex Bio Science, Walkersville, MD, USA) were cultured
in osteoblast growth medium (OGM) supplemented with 10%
fetal calf serum (FCS), 5 µM sodium ascorbate and 100 µg/mL
penicillin/100 IU μg/mL streptomycin (Lonza, Allendale, NJ,
USA). NHOs were mixed in a 4:1 ratio with normal osteoclast
precursor cells derived from human peripheral blood mononuclear cells (PBMC) (Lonza) cultured in osteoclast precursor
basal medium containing 10% FCS, human recombinant macrophage colony-stimulating factor (M-CSF) (50 ng/mL), and
human recombinant RANKL (50 ng/mL) (Lonza), with and
without adiponectin (0.08 µg/mL) (BioVision Inc., Milpitas,
CA, USA). At day 7, media were supplemented with hydrocortisone hemisuccinate (200 nM) and β-glycerophosphate
(10 mM) (Lonza). Osteospheres were generated using disposable 10 mL high-aspect-ratio vessels (Synthecon, Houston,
TX, USA) in an RCCS operated in a 5% CO2 humidified
tissue culture incubator maintained at 37°C (9). Osteospheres
were harvested after 21 days in the RCCS. The adiponectin
concentration was based on Berner et al. (30), where adiponectin concentration in the mice bone marrow was found
to be between 0.1 and 0.15 µg/mL. Osteospheres of various
sizes were generated and only the largest spheres (~0.5–1 mm)

2

May 2018 | Volume 9 | Article 236

Haugen et al.

Adiponectin Reduces Bone Stiffness

plane to assess stress (i.e., stress = punch force/πab, where a
and b are the magnitude of the semi-axes), and the resultant
displacement was divided by height of specimen to get a strain
measure (i.e., strain = global displacement/height of sphere).
The largest spheres (~0.5–1 mm) were chosen to obtain easier
handling during experimental preparation. Due to large mass,
the mechanical parameters obtained from these were based on
average properties of more material, and the data less influenced
by local artifacts.

were used for mechanical testing. The osteospheres used for
histology were harvested and stored in −70°C until further use.

Micro-Computed Tomography
of Osteospheres

The osteospheres from primary human osteoblasts and osteoclasts were scanned using a SkyScan 1176 (Bruker, Kontich,
Belgium) at 9 µm voxel size. 3D reconstructions were made
using Medical Image Segmentation for Engineering on Anatomy
(MIMICS) software (Materialize HQ, Leuven, Belgium). The
reconstructed geometries were used to identify global measures,
such as overall height and extension and shape of the cross section at the equatorial plane. These data were employed in finding
stress and strain measures from the measured global force and
displacement in the mechanical testing of the osteospheres
(see next section).

Microscopy Analysis of Osteospheres

Osteospheres were removed from RCCS for histologic cha
racterization after 21 days of culturing, fixed in 4% formalde
hyde (VWR, Radnor, PA, USA), dehydrated in ascending
concentrations of ethanol and embedded in paraffin for histological analysis. Sections were cut and mounted on glass slides.
Before staining, sections were de-paraffinized and rehydrated
through graded ethanol rinses. Slides were stained with either
Hematoxylin and Eosin (i.e., cell nuclei) or Alizarin Red
(i.e., calcium) stain using standard protocols and imaged using
a Leica DM RBE microscope (Leica, Wetzlar, Germany) with a
digital camera. Original images were taken with resolution of
1.08 pixels per micron.
De-paraffinized and rehydrated sections were stained to detect
cell nuclei and the protein periostin by confocal microscopy.
Antigen retrieval was carried out with 10 mM citrate buffer pH
6.0 with 0.05% Tween20, 30 min at 95°C, before cooling to room
temperature and permeabilizing with 0.3% Triton X-100 for
30 min. After washing with PBS, sections were blocked in 10%
normal goat serum (NGS) (Abcam, Cambridge, UK) with 0.1%
Triton X-100 (Sigma-Aldrich, St. Louis, MO, USA) in PBS for 1 h
room temperature. Sections were immunolabeled with rabbit antiperiostin (ab14041, Abcam) diluted 1:300 in 2% NGS in PBS at
4°C overnight, washed three times with PBS, then incubated with
Alexa488 goat anti-rabbit secondary antibody (ThermoFisher,
Waltham, MA, USA) diluted 1:400 in 4% NGS in PBS, 1 h, room
temperature. After washing three times with PBS, sections were
co-stained with 300 nM 4′,6-diamidino-2-phenylindole, dihydrochloride (DAPI) (Sigma-Aldrich) for 30 min and mounted
with Prolong Diamond (ThermoFisher, Waltham, MA, USA).

Mechanical Testing of Osteospheres

The mechanical response of the osteospheres at room temperature was characterized by nanoindentation using Hysitron TI950
TriboIndenter® (Hysitron, Minneapolis, MN, USA). Because of
irregular geometry of samples, the conventional nanoindentation was not applicable. Instead, a so-called flat punch method
for compression test of particle-like materials was used (44). The
osteospheres were placed on a silicon chip and compressed with
a diamond flat punch with a diameter of 1.08 mm, comparable
with sample size, see Figure 1A for an illustration of the setup
and boundary conditions. The maximum load 1 N was applied
to each sample. The predefined loading function consisted of 20
partially loading–unloading cycles; a linear loading segment to
peak load in 10 s, a 0.1 s holding segment at peak load, and a
10 s linear unloading segment within one cycle, see Figure 1B
for the loading scheme (including the loading rate). The cyclic
loading condition was used to counterbalance the viscoelastic
effect of bone materials. The real-time displacement of the
samples was recorded and analyzed. To remove some of the
geometry effects on the mechanical response of the spheres,
a simple conversion to nominal stress and strain was carried
out. Based on the reconstructed MIMICS images, the applied
force was divided by elliptical cross section area at equatorial

Figure 1 | A schematic illustration of the flat punch method for compression test of particle-like materials is shown in panel (A) and the loading scheme
is illustrated in panel (B).
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Identification of the Effect of Adiponectin
on Human Bone Cells

Slides were viewed with a 10×/0.40 HCX PL APO CS objective
lens on a Leica SP8 confocal microscope (Leica) using 405 and
488 nm excitation, and 410–470 and 500–550 nm emission filters
for DAPI and Alexa488, respectively. Original images were taken
with resolution of 2.77 pixels per micron. Images were viewed and
processed in ImageJ (45).

NHOs from both femur and tibia of different donors (Cambrex
Bio Science) were grown in OGM (Cambrex Bio Science). The
cells were incubated with either 0.08, 0.4, or 2 µg/mL recombinant adiponectin (R&D Systems, Minneapolis, MN, USA) for
1 and 3 days, and the effect on incorporated 3H-thymidine was
calculated relative to untreated cells at the same time points.
Effect on proliferation rate of NHO cells was measured after a
12 h pulse with 3H-thymidine as previously described (50).
The effect of adiponectin (0.08, 0.4, and 2 µg/mL) on differentiation of osteoblasts was measured after 1, 3, 7, and 14 days of
incubation. The concentration of various bone markers secreted
in the cell culture medium was evaluated, and the phenotype
of the cells was characterized based on the mRNA expression
levels of runt-related transcription factor 2 (RUNX2), collagen
type I alpha 1 (COLIA1), osteocalcin (OC) (BGLAP), and CD44
(CD44).
The effect of adiponectin (0.08, 0.4, and 2 µg/mL) on calcium
(Ca2+) deposition in primary human osteoblasts was measured
after 21 days of incubation and compared with unexposed
controls. The cells were washed with PBS, fixed in 95% ethanol
and stained with 1% Alizarin Red (Sigma-Aldrich, St. Louis, MO,
USA) as described elsewhere (51). Alizarin Red was extracted
with cetylpyridinium chloride (Sigma-Aldrich) at room temperature, measured spectrophotometrically at 562 nm (ELx800
Absorbance Reader, BioTek instruments, Winooski, VT, USA)
and presented relative to untreated cells.
Osteoclasts were differentiated from PBMC isolated from
buffy coat, performed essentially as described by Bøyum (52).
Cells were seeded into 24-well dishes, 5.0 × 105 cells/well in
MEMα/10% FCS including M-CSF and RANKL (50 ng/mL
of both), and dexamethasone (0.1 µM) (Sigma-Aldrich) with
or without 0.1 µg/mL adiponectin (Phoenix Pharmaceuticals,
Belmont, CA, USA). Assays were performed in triplicate. The
medium was replaced at days 6 and 9. After 12 days, the cells
were stained for tartrate resistant acid phosphatase (TRAP)
using an acid phosphatase kit (Sigma-Aldrich), as described by
the manufacturer. TRAP-positive, multinuclear (three or more
nuclei) cells were regarded as genuine osteoclasts. To investigate
direct osteoclast activity, a pit resorption assay was performed.
Osteoclast activity (resorption) was evaluated by analyzing the
amount of digested area by osteoclasts seeded and differentiated on hydroxyapatite disks (BD Biosciences, ON, Canada).
PBMC were seeded on hydroxyapatite disks in 24-well dishes in
osteoclast differentiation media with or without adiponectin, as
described earlier. After 12 days, the amount of digested area was
measured using a Bioquant scanner (Bioquant Image Analysis,
Nashville, TN, USA).

Relationship Between Adiponectin
Expression and Biomechanical Data
of Rat Femurs

Data on rat bones were retrieved from three studies on female
Fisher 344 rats given the following PPAR agonists: Wyeth 14643
(90.0 mg/kg/day Wyeth 14643) (ChemSyn Laboratories, USA)
(unpublished data), fenofibrate and pioglitazone (46), and tetradecylthioacetic acid (TTA) (47) dissolved in methylcellulose,
or methylcellulose alone, for 4 months as described previously
(46, 47). All animal experiments were approved by the Regional
Animal Research Authority at the Norwegian University of
Science and Technology, and the Federation of Laboratory
Animal Science Associations guidelines were followed. Blood
was collected by heart puncture during the final anesthesia, and
plasma samples were stored at −80°C until analyzes. Femurs from
23 animals were randomly picked for biomechanical analysis
from the different treatment groups in three larger animal studies (fenofibrate n = 8; Wyeth n = 6; TTA n = 3; pioglitazone
n = 3; untreated n = 3). The femurs were fractured 18.7 mm
from the femoral condyles in the so-called three point cantilever bending setup that has been described in detail elsewhere
(48, 49). Briefly, the proximal femur was fixed in a clamp, and
bending of the distal part of the femur was performed by a rotating wheel with a fixed cam applying bending force to the femoral
condyle with a fulcrum positioned 18.7 mm anteriorly from the
condyle acting as the third point of force application. All tests
were done at a loading rate of 0.095 rad/s (5.43°/s), and the load
was applied until fracture at the fulcrum occurred. The load in
the test apparatus, a MTS 858 Mini Bionix® Axial/Torsional Test
System (MTS Systems Corporation, MN, USA), was measured
with an MTS Test Star TM Sensor Cartridge Force 250 N load
cell and registered in MTS Test Star II software. Ultimate bending
moment (M) was calculated as the ultimate load before failure
multiplied by the moment arm by which the load was applied
(Nm). Ultimate energy absorption, stiffness, and deflection were
read directly or calculated from computer recordings (48). After
mechanical testing, the femurs were homogenized in liquid
N2, and 200 mg tissue of each sample was aliquoted in Trizol
(Invitrogen, Carlsbad, CA, USA). Messenger ribonucleic acid
(mRNA) and proteins were extracted according to the manufacturers’ instructions (Invitrogen). The concentration of adiponectin in plasma and in protein extracts from femurs was quantified
by a Mouse Adiponectin Radioimmunoassay (RIA) kit (Linco,
St. Charles, MI, USA) and a Mouse adiponectin enzyme-linked
immunosorbent assay (ELISA) kit (Linco, St. Charles, MI, USA),
respectively. Relative abundance of adiponectin was calculated as
ratios of the total protein content [25 μL of each sample diluted
1:10 using Bicinchoninic acid (BCA) Protein Assay Kit (Pierce
Biotechnology, Rockford, IL, USA)].

Frontiers in Endocrinology | www.frontiersin.org

Quantification of Secreted Proteins
in Cell Culture Media

Before analyses, aliquots of the cell culture medium were concentrated 10-fold using centrifugation filters with 3 kDa cutoff
(VWR international, Radnor, PA, USA) according to manufacturer’s instruction. Multi-analyte profiling of the protein level in
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concentrated cell culture medium of primary human osteoblasts
was performed on Luminex 200 system (Luminex, Austin, TX,
USA) using xMAP technology. Acquired fluorescence data were
analyzed by the xPONENT 3.1 software (Luminex). The effect
of adiponectin on the secretion of bone markers to the culture
medium was measured using the Milliplex Human Bone Panel
kit [interleukin-1 (IL-1β), interleukin-6 (IL-6), OPG, OC, leptin,
osteopontin (OPN), parathyroid hormone, TNF-α, adrenocorticotropic hormone, Dickkopf-related protein 1 (DKK1), sclerostin
(SOST), and insulin] (Millipore, Billerica, MA, USA) after 1, 3, 7,
and 14 days of culture. All analyses were performed according to
manufacturers’ protocols.

Table 1 | Description of the rat (r) and human (h) oligonucleotide primers used
for qPCR.

Isolation of mRNA From Cells

Cells were lysed in lysis/binding buffer [100 mM Tris–HCl,
pH 8.0, 500 mM LiCl, 10 mM ethylenediaminetetraacetic acid,
pH 8.0, 0.5 mM dithiothreitol, and 1% sodium dodecyl sulfate
(Sigma-Aldrich)]. mRNA was isolated using magnetic beads
[oligo (dT) 25] as described by the manufacturer (Dynal AS,
Oslo, Norway). Beads containing mRNA were suspended in
10 mM Tris–HCl, pH 8.0, and stored at −70°C until use. 10 µL
of the mRNA-containing solution was applied directly to obtain
a first-strand complementary cDNA using the iScript cDNA
Synthesis Kit containing both oligo (dT) and random hexamer
primers (Bio-Rad, Hercules, CA, USA).

Gene

Primer sequence (5′–3′)

Adiponectin

r-ADIPOQ
r-ADIPOQ

f AATCCTGCCCAGTCATGAAG
r CATCTCCTGGGTCACCCTTA

Glyceraldehyde3-phosphate
dehydrogenase

r-GADPH
r-GADPH

f ATGATTCTACCCACGGCAAG
r CTGGAAGATGGTGATGGGTT

β-Actin

r-ACTB
r-ACTB

f CCTCTATGCCAACACAGT
r AGCCACCAATCCACACAG

Collagen type I
alpha 1

h-COL1A1
h-COL1A1

f CCAAATCCGATGTTTCTGCT
r CATCTCCCCTTCGTTTTTGA

Alkaline phosphatase

h-ALPL
h-ALPL

f AGACTGCGCCTGGTAGTTGT
r GACAAGAAGCCCTTCACTGC

Runt-related
transcription factor 2

h-RUNX2
h-RUNX2

f GCCTTCAAGGTGGTAGCCC
r CGTTACCCGCCATGACAGTA

CD44

h-CD44
h-CD44

f CAAGTTTTGGTGGCACACAGC
r GAAGCAATATGTGTCATACTGGGAG

Glyceraldehyde3-phosphate
dehydrogenase

h-GADPH
h-GADPH

f TGCACCACCAACTGCTTAGC
r GGCATGGACTGTGGTCATGAG

β-Actin

h-ACTB
h-ACTB

f CTGGAACGGTGAAGGTGACA
r AAGGGACTTCCTGTAACAATGCA

Osteocalcin

h-BGLAP
h-BGLAP

f CACTACCTCQCTQCCCTCC
r QAAQCCCAQCQQTQCA

qPCR, quantitative polymerase chain reaction; f, forward; r, reverse.

Quantitative Polymerase Chain Reaction
(qPCR) Quantification of Gene Expression

t-test or Mann–Whitney U test. A probability of less than or equal
to 0.05 was considered significant.

Gene expression was monitored using iCycler iQ and CFX connect (Bio-Rad). The 2× iQ SYBR Green Supermix was based on
iTaq DNA polymerase (Bio-Rad). cDNA samples (1 µL for a total
volume of 25 µL per reaction) were analyzed both for the genes
of interest and the reference genes [β-actin and glyceraldehyde3-phosphate dehydrogenase (GAPDH)]. The cycling profile was
as follows: denaturing at 94°C for 5 min followed by 40 cycles of
annealing at 57°C for 30 s, primer extension at 72°C for 30 s, and
denaturing at 95°C for 30 s. Finally, one cycle for 3 min of extension completed the reaction. Reactions were replicated twice on
a 96-well plate. Cycle threshold (Ct) values were obtained graphically. Gene expression was normalized to β-actin and GAPDH
and presented as ΔCt values. Comparison of gene expression
between control and treated samples was derived from subtraction of control ΔCt values from treatment ΔCt values to give a
ΔΔCt value, and relative gene expression was calculated as 2−ΔΔCt.
The efficiency of each set of primers was always higher than 90%.
The sequences of the oligonucleotides are shown in Table 1.

RESULTS
Adiponectin Reduces the Stiffness
of Osteospheres

Micro-computed tomography scans identified irregularly shaped
osteospheres (0.5–1 mm). The global response of the spheres, i.e.,
the flat punch force versus displacement. The global response of
the spheres, i.e., nanoindentation force versus displacement, is
shown in Figure 2A whereas the corresponding nominal stress–
strain response is shown in Figure 2B. The tangent stiffness was
obtained by the line connecting the stress at each cyclic peak load
and found to be 6.47 and 16.93 MPa for osteospheres with and
without adiponectin exposure, respectively. Elastic stiffness of
the osteospheres was estimated from the unloading sections of
the stress–strain curves using the sixth unloading/loading cycle
and was much lower for the adiponectin-treated osteosphere
(17.4 MPa) compared with control (37.6 MPa). The pop-in on
initial section of the loading curve of the control was considered
to arise from collapse of the pore found within this osteosphere.

Statistics

The differences between the mechanical variables were tested
with one way ANOVA. The relationship between mechanical
data and adiponectin expression was tested by Spearman rank
order correlation. Comparison between data obtained from the
various groups and treatments by ELISA and RIA measurements
was performed using the non-parametrical tests one way ANOVA
or Mann–Whitney U test. qPCR (ΔΔCt values), Luminex, proliferation, and Alizarin Red quantification data were analyzed by

Frontiers in Endocrinology | www.frontiersin.org

Protein

Morphological Characteristics
of Osteospheres

Sections of 21-day-old mineralized constructs showed round
osteospheres with a lobulated appearance. This may be explained
by multiple smaller osteospheres that seemed to have merged
(Figure 3A). It consisted of distinct units previously described
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Figure 2 | Compression force–displacement curves and stress–strain relationship of osteospheres treated with (blue line) and without (red line) adiponectin.
The global response of the spheres, i.e., nanoindentation force versus displacement is shown in panel (A). The corresponding nominal stress–strain response is
illustrated in panel (B). Notable difference in the stiffness of the two osteospheres was observed as the tangent stiffness of the adiponectin-treated osteospheres
was considerably lower than that of the control sample.

or deflection (p = 0.071) of the femur between the different
experimental groups tested (Table 2).
The relative expression of adiponectin mRNA in femur of the
rats were measured and the difference between the groups was
not significant (p = 0.066), possibly due to the limited number of
samples in each group (Figure 5).
The correlation test between adiponectin mRNA expression
levels and mechanical parameters show that the relative expression of adiponectin mRNA in the femur positively correlated
to ultimate bending moment, ultimate energy absorption and
deflection, and negatively to bending stiffness (Table 3).
The mean concentration of adiponectin isolated from the
bone samples was 38.2 ± 10.5 ng/200 mg bone mass (n = 23);
48.4 ± 8.0 ng in the control group, 38.3 ± 10.3 ng in the group
receiving the PPARpan agonist TTA, 42.4 ± 9.3 ng in the groups
receiving the PPAR gamma agonist pioglitazone, and 37.8 ± 7.1 ng
and 31.4 ± 13.6 ng, respectively, in the groups receiving the PPAR
alpha agonists fenofibrate and Wyeth. No significant differences
were found between the groups.
The quantified adiponectin levels in the protein fractions
isolated from femur were negatively associated with stiffness;
however, not statistically significant (Table 2).
No significant relationship between circulating plasma
adiponectin levels and the bone biomechanical data was found
(Table 3).

Figure 3 | The osteospheres has a lobulated appearance with two
morphologically different regions shown here in section stained with
hematoxylin and eosin (scale bar = 100 µm) (A). In this osteosphere, the
outer region of the sphere and region between the lobuli the osteosphere
contained cells (A). Mineralization of the extracellular matrix is visualized
by Alizarin Red staining (B). In the inner region of the lobuli, sections
show few cells embedded in bone-like material (C).

by Clarke et al. as osteoclasts and osteoblasts that are situated in
the outer region of the spheres (9). Alizarin Red staining showed
an inner region of the spheres containing calcium (Figure 3B),
with individual cells trapped within the tissue as indicated by
hematoxylin (Figure 3C) and DAPI (Figures 4A,C) staining of
cell nuclei. The osteoblasts in the inner region of the osteospheres
produced collagen as expected, shown by periostin positive staining (Figures 4B,C).

Adiponectin Enhanced Bone Cell
Proliferation and the Expression of
Collagen mRNA

The effect of adiponectin (0.08, 0.4, and 2 µg/mL) on the proliferation rate of osteoblasts was calculated as counts per minute
in percent of untreated control at each time point (Figure 6).
Enhanced proliferation was observed after both 1 and 3 days of
incubation compared with control.
The levels of selected protein markers associated with differentiation and mineralization of NHOs were quantified, and OC,

Relationship Between Adiponectin
Expression and Mechanical Properties
of Rat Femurs

The biomechanical data are given in Table 2. There were no significant differences in ultimate bending moment (p = 0.257), ultimate energy absorption (p = 0.273), bending stiffness (p = 0.692),
Frontiers in Endocrinology | www.frontiersin.org

6

May 2018 | Volume 9 | Article 236

Haugen et al.

Adiponectin Reduces Bone Stiffness

Figure 4 | Immunohistochemical characterization of cell nuclei and periostin in paraffin embedded sections of 21-day-old mineralized osteospheres stained with
4′,6-diamidino-2-phenylindole, dihydrochloride (nuclei) (green) (A) and periostin (purple) (B) and both (C) (scale bar = 200 µm). The outer region contained cells
whereas the inner region was made up of osteoblasts embedded in self-produced extracellular matrix with collagen indirectly visualized by periostin (C). The last
image (D) is a bright-field version.

not affected by the same dosage of adiponectin compared with
control as no significant difference was observed in the relative
area of digested hydroxyapatite by osteoclasts incubated with or
without adiponectin (Figure 11).

Table 2 | Mechanical data for bending of rat femurs (n = 23).

All groups
(n = 23)
Control
TTA
Pioglitazone
Wyeth 14643
Fenofibrate

M (Nm)

Ultimate energy
absorption (J)

Stiffness
(Nm/°)

Deflection (°)

45.7 ± 3.7

1.07 ± 0.09

1.03 ± 0.10

16.2 ± 1.9

48.4 ± 1.6
43.3 ± 2.0
43.4 ± 5.6
45.0 ± 2.9
47.0 ± 3.9

1.13 ± 0.04
1.01 ± 0.05
1.01 ± 0.13
1.05 ± 0.07
1.10 ± 0.09

0.98 ± 0.18
1.07 ± 0.07
1.08 ± 0.13
1.03 ± 0.10
1.00 ± 0.07

17.9 ± 3.0
14.8 ± 1.0
14.5 ± 1.3
15.9 ± 1.6
17.0 ± 1.5

DISCUSSION
This study demonstrates that adiponectin is associated with
reduced bone stiffness, both in osteospheres in vitro and in rat
femurs in vivo. Adiponectin seemed to directly influence bone
by regulating proliferation and differentiation of osteoblasts and
osteoclasts and alter the expression of ECM proteins.
In vitro created tissues are dependent on extracellular scaffolding, and in most models synthetic or non-synthetic biomaterials are used (4, 6, 10, 11). Recently, an interesting model
of bone tissue formation in vitro has been presented (12).
Iordachescu et al. used monocultures of animal bone cells and
cell lines, and their model is dependent on a premade fibrin gel
cast between scaffolds anchors (12). This is in contrast to the
two-cell system presented here, where primary human osteoblasts and osteoclasts are integrated in a spheroid with their
secreted ECM proteins. In vitro produced osteospheres have
the advantage that direct effects on the two primary cell types
of bone can be investigated, and in contrast to an in vivo setting,
complex biological responses may be measured in this simplified
model of bone (9).
This method gives the opportunity to investigate effects on
mechanical properties. To the best of our knowledge, this is the
first report on induced changes in mechanical properties of a
human cell-based bone model. Potential limitations in the use
of these bone-like tissues may be related to the reproducibility
of the shape and size of the constructs. In addition, the distribution of the cells and ECM within the constructs may differ. The
osteospheres in this study varied from 0.5 to 1 mm and were
significantly smaller, but had the similar morphological features
as described by Clarke et al. (9).
We aimed at producing and treating osteospheres with
adiponectin at levels within or below physiological range.
Plasma levels of adiponectin have been found to be around
6–8 µg/mL in humans (53). Furthermore, Berner et al. found
the levels of adiponectin in the bone marrow fluid of mice to

Data presented as mean ± SD.
TTA, tetradecylthioacetic acid.

OPN, SOST, and DKK1 were not affected by adiponectin treatment, whereas leptin secretion was more than threefold enhanced
(p < 0.01) on day 7 by the lowest dosage (0.08 µg/mL) and
more than twofold (p < 0.001) by the highest dosage (2 µg/mL)
of adiponectin (Figure 7A). Adiponectin (2 µg/mL) treatment
resulted in an initial twofold increase in the release of TNF alpha
(p < 0.01), whereas after 7 days of incubation all dosages of
adiponectin (0.08, 0.4, and 2 µg/mL) significantly increased TNF
alpha levels (p < 0.001, p < 0.05, and p < 0.001, respectively),
and after 14 days of culture a significantly higher amount was
detected compared with control with 0.4 and 2 µg/mL adiponectin (p < 0.001 and p < 0.001, respectively) (Figure 7B).
The mRNA expression levels of COLIA1, BGLAP, and CD44
in NHOs is shown for two adiponectin concentrations (0.4 and
2 µg/mL) at selected time points (1, 3, 7, and 14 days) (Figure 8).
Incubation with 2 µg/mL adiponectin induced a more than eightfold enhancement of COLIA1 expression (p < 0.05) compared
with unexposed cells on day 1 (Figure 8A).
High dosage of adiponectin (2 µg/mL) enhanced the Ca2+
deposition in osteoblasts after 21 days of incubation, while no
statistically significant difference was detected for the lower adiponectin concentrations in comparison to the untreated control
(Figure 9).
Evaluation of the number of differentiated osteoclasts after
treatment with or without 0.1 µg/mL adiponectin revealed that
adiponectin enhanced the differentiation of osteoclasts from
human peripheral monocytes compared with untreated cells
(p < 0.01) (Figure 10). However, the osteoclast activity was

Frontiers in Endocrinology | www.frontiersin.org

7

May 2018 | Volume 9 | Article 236

Haugen et al.

Adiponectin Reduces Bone Stiffness

Figure 5 | The relative expression of adiponectin messenger ribonucleic acid (mRNA) in rat femur in the different treatment groups are shown. There were no
significant differences between the groups. Data are expressed as mean ± SD.

Table 3 | Correlation between adiponectin messenger ribonucleic acid (mRNA)
and protein in bone, adiponectin in plasma, and mechanical properties in rats
(n = 23).
M (Nm)

Ultimate energy
absorption (J)

Stiffness
(Nm/°)

Deflection (°)

mRNA
(bone)

r
p

0.773
<0.001

0.733
<0.001

−0.506
0.014

0.988
<0.001

Adiponectin
(bone)
Adiponectin
(plasma)

r
p
r
p

0.126
0.561
−0.029
0.890

0.126
0.561
−0.252
0.242

−0.0845
0.696
−0.164
0.450

0.0647
0.764
−0.164
0.450

Correlation coefficient: r (Spearman rank order correlation).

be between 0.1 and 0.15 µg/mL. A concentration of 0.01 µg/mL
adiponectin was found to enhance the proliferation of human
osteoblasts; however, there were no dosage-dependent variations between 0.01 and 2.0 µg/mL of adiponectin on cell growth
in vitro (30).
Reduced stiffness was observed in adiponectin-treated artificial bone compared with control bone measured by flat punch
compression nanoindentation. Conventional nanoindentation
with a sharp indenter [pyramidal (Berkovich) or spherical] is a
well-established method where the local properties of the bone
is investigated to determine the hardness and modulus (54, 55).
With this method, the response of the material is measured in a
local region below the indenter where the tissue deformations
are localized. For soft materials, that kind of indentations can
introduce local tissue damage, and consequently it may be
difficult to extract the basic material properties describing the
stress–strain response for undamaged material. In such cases,
the conventional indenter is not applicable, and a flat punch
method for compression test has been developed (44, 56).
The flat punch method gives the opportunity to avoid local

Frontiers in Endocrinology | www.frontiersin.org

Figure 6 | Effect of adiponectin on cell growth of primary human
osteoblasts after 1 and 3 days measured as 3H-thymidine incorporation in
counts per minute (CPM). Adiponectin (0.08, 0.4, and 2 µg/mL) significantly
enhanced the proliferation of primary human osteoblasts on both time points
compared with control. Values represent the mean ± SD of one experiment
with three parallels. Significantly different from control at *p < 0.05,
**p < 0.01, and ***p < 0.001.

damage from a sharp indenter, and material properties that
are more representative for the whole specimen are obtained.
Furthermore, the shape of the osteospheres is important with
respect to deriving mechanical properties (i.e. stress versus
strain). Because of irregular samples, the flat punch method
was conducted in this study, and a simplistic analysis was made
based on global geometry such as size of equatorial plane and
the height of the specimen. In further work, one could establish
more detailed finite element models. A disadvantage of the use
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Figure 7 | Secretion of leptin (A) and tumor necrosis factor-α (TNF-α) (B) to culture medium from primary human osteoblasts treated with and without adiponectin
is presented in percentage of control at 1, 3, 7, and 14 days. Adiponectin (0.4 and 2 µg/mL) treated osteoblasts showed upregulated levels of leptin (A) and TNF-α
(B). Values represent the mean of two donors ± SD. Significantly different from control at *p < 0.05, **p < 0.01, and ***p < 0.001.

Figure 8 | Relative messenger ribonucleic acid expression levels for COLIA1 (A), BGLAP (B), and CD44 (C) in human primary osteoblasts cultured with 0.4 and
2 µg/mL adiponectin normalized to reference genes GAPDH and ACTB and presented as fold change relative to controls. Adiponectin enhanced expression of
COLIA1 (A) more than eightfold compared with untreated cells after 1 day. Values represent the mean ± SD. Significantly different from control at *p < 0.05 and
***p < 0.001.

of spheres in mechanical indentation testing may be the variable inner structure, irregular geometry, and degree of mineralization of the spheres. The relation between adiponectin and
reduced stiffness of bone is in accordance with a recent study
reporting cortical bone hardness to be 15% higher in 8-weekold APN-KO mice (57).
Adiponectin is abundant in plasma (22) and as previously
mentioned epidemiological studies have consistently shown
an inverse association between circulating adiponectin and
BMD (14, 15), whereas in animal studies the reported effects of
adiponectin on bone are inconsistent (13). There are indications
that both adipokines and PPAR agonists play important roles
in the regulation of bone metabolism (58). Administration of
PPAR agonists may have different effects on circulating adiponectin levels in rats. Increased plasma levels of adiponectin
in rats given the PPAR gamma agonists pioglitazone (46) and
thiazolidinedione (59) have previously been demonstrated,
while rats receiving the PPAR alpha agonist fenofibrate exhibited decreased levels (46). Yet, in the protein fractions isolated

Frontiers in Endocrinology | www.frontiersin.org

from flushed femur, the content of adiponectin was similar in
the groups receiving different PPAR agonists (46). This study
showed an association between the mechanical properties of rat
femurs with in situ elevated adiponectin expression, supporting
that adiponectin is associated with reduced stiffness of bone.
In contrast to reports from human studies (14, 15), the effect
was not associated with the levels of circulating adiponectin
but to the adiponectin mRNA levels locally in femur, indicating
an autocrine and/or paracrine effect of adiponectin on bone.
A limitation to this study is the low number of samples. Yet,
the negative correlation between adiponectin expression and
femur stiffness is in accordance with Kajimura and coworkers,
who found that bone was more resistant in terms of mechanical
strength in APN-KO mice (28).
Adiponectin has previously been reported to enhance osteoblast mineralization (37). We observed no significant difference
in mineralization status in 2D osteoblast cultures exposed to low
adiponectin dosages compared with unexposed cells, but the same
low dosage was shown to reduce stiffness of the osteospheres. The
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Figure 11 | No significant changes were seen in the relative area of
digested hydroxyapatite from osteoclasts incubated with and without
adiponectin (0.1 µg/mL). Data are presented as mean ± SD.

Figure 9 | Quantification of Ca2+ deposits from primary human osteoblasts
after 21 days of adiponectin treatment. Ca2+ deposition was significantly
enhanced from osteoblasts by adiponectin (2 µg/mL) compared with
untreated control cells. Data presented as means ± SD. Significantly different
from untreated controls at *p < 0.05.

The extent to which these findings translate to bone remains to
be investigated.
Regarding the effects of adiponectin on osteoclast differentiation and osteoclast activity, diverging results have been
reported. Most studies show suppressing effect of adiponectin
on osteoclastogenesis (33, 36, 39–41), while others report indirect increase of osteoclast formation via RANKL/OPG pathway
(42, 43). In this study, recombinant adiponectin enhanced
the number of differentiated osteoclasts from primary human
monocytes, while no change in activity was observed. Our data
are in accordance with Williams et al. who found no effect of
adiponectin on osteoclast activity (39), on the other hand, in
contrast to Oshima et al. reported suppressing bone-resorption
activity of adiponectin-treated osteoclasts (36).
In conclusion, this study indicates that adiponectin is involved
in bone stiffness. In addition, we hypothesize that artificial
osteospheres produced in an RCCS without scaffolding material
may be a model system for testing the effects of different agents
on the mechanical features of bone. However, further studies are
required.

Figure 10 | Adiponectin enhanced the number of mature osteoclasts
differentiated from human mononuclear cells. Data are presented as
mean ± SD (**p < 0.01).
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increased proliferation and collagen expression by adiponectin
stimulation may indicate that the osteoblasts remain in a proliferative state (60). This is in accordance with a previous study
reporting both enhanced osteoblast proliferation and collagen
expression after adiponectin stimulation (34). Collagen provides
the flexibility (toughness) to the bone structure, contributing to
resistance to impact loading (61, 62). The mechanical properties
of bone are dependent on both the amount and orientation of
collagen fibers (63). Adiponectin has been shown to play a role in
wound healing in mice by upregulation of keratin gene transcripts
and subsequently promoting collagen organization, thickness,
and deposition (64). Also, adiponectin has been shown to enhance
the production of collagen III and elastin in fibroblasts (65).
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